PMID- 36295633
OWN - NLM
STAT- MEDLINE
DCOM- 20221028
LR  - 20230308
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Print)
IS  - 1010-660X (Linking)
VI  - 58
IP  - 10
DP  - 2022 Oct 17
TI  - Application Value of Systemic Inflammatory Indexes in the Clinical Evaluation of 
      Patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
LID - 10.3390/medicina58101473 [doi]
LID - 1473
AB  - Background: In areas where medical resources are scarce, an economical and 
      convenient way to assess patients' condition so that treatment plans can be 
      adjusted in a timely manner makes sense. The clinical value of systemic 
      inflammatory indexes (SII) such as neutrophil-to-lymphocyte ratio (NLR), 
      lymphocyte-to-monocyte ratio (LMR), albumin-to-gamma-glutamyl-transferase ratio 
      (AGR), white-blood-cell-count-to-mean-platelet-volume ratio (WMR), 
      high-density-lipoprotein-cholesterol-to-C-reactive-protein ratio (HCR), etc. were 
      explored in heart failure (HF) with preserved ejection fraction (HFpEF) because 
      of their easy availability and clinical value in the diagnosis, therapy and 
      prognosis of cardiovascular diseases. Methods: 189 inpatients (including 48 
      patients with New York Heart Association (NYHA) I in the control group, and 141 
      patients with NYHA II-IV in the study group) from The First Affiliated Hospital 
      of Jinan University, during the period July 2018 to March 2022, were included by 
      retrieving electronic medical records. Logistic regression analysis, Spearman's 
      correlation coefficient, operating characteristic curve, etc. were used to 
      analyze the data. Results: In patients with HFpEF, LMR (OR = 0.463, 95% CI 
      0.348-0.617, p = 0.000), NLR and N-terminal pro-B-type natriuretic peptide 
      (NT-proBNP) were independent predictors for the presence of HF, and LMR (OR = 
      2.630, 95% CI 2.016-3.435, p = 0.000), NLR, FAG, MHR, AGR and NT-proBNP were 
      independent predictors for increased NYHA functional classification. There were 
      good correlations (r > 0.4) between LMR (r = -0.667, p = 0.000), NLR, WMR, HCR, 
      NT-proBNP (r = -0.681, p = 0.000) and NYHA functional classification, and LMR 
      (AUC = 0.803, 95% CI 0.729-0.849, p = 0.0001), NLR and NT-proBNP (AUC = 0.805, 
      95% CI 0.738-0.861, p = 0.0001) had good diagnostic values (AUC > 0.7) for HF in 
      patients with HFpEF. In addition, there were certain correlations between LMR, 
      NT-proBNP and echocardiography indicators of cardiac structural. Conclusions: SII 
      have a potential application value in the clinical evaluation of patients with 
      HFpEF in the follow-up, especially in areas with limited medical resources, as 
      they are more convenient and cost effective. Among different SII, LMR is probably 
      the most promising metric. However, large-scale clinical trials are needed in the 
      future to confirm these findings.
FAU - Wang, Ruxin
AU  - Wang R
AD  - Department of Endocrinology and Metabolism, The First Affiliated Hospital of 
      Jinan University, Guangzhou 510630, China.
FAU - Wu, Juan
AU  - Wu J
AD  - Clinical Laboratory, Suqian First People's Hospital Affiliated to Nanjing Medical 
      University, Suqian 223812, China.
FAU - Ye, Haowen
AU  - Ye H
AD  - Department of Endocrinology and Metabolism, The First Affiliated Hospital of 
      Jinan University, Guangzhou 510630, China.
FAU - Zhang, Xiaofang
AU  - Zhang X
AD  - Clinical Experimental Center, The First Affiliated Hospital of Jinan University, 
      Guangzhou 510630, China.
FAU - Wang, Lihong
AU  - Wang L
AD  - Department of Endocrinology and Metabolism, The First Affiliated Hospital of 
      Jinan University, Guangzhou 510630, China.
LA  - eng
GR  - 808026/Jinan University/
PT  - Journal Article
DEP - 20221017
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 0 (Biomarkers)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 0 (Lipoproteins)
RN  - EC 2.- (Transferases)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Humans
MH  - *Natriuretic Peptide, Brain
MH  - Stroke Volume
MH  - *Heart Failure/diagnosis
MH  - Biomarkers
MH  - Prognosis
MH  - C-Reactive Protein
MH  - Lipoproteins
MH  - Transferases
MH  - Cholesterol
PMC - PMC9611882
OTO - NOTNLM
OT  - HFpEF
OT  - NT-proBNP
OT  - New York Heart Association (NYHA)
OT  - lymphocyte-to-monocyte ratio (LMR)
OT  - systemic inflammatory indexes (SII)
COIS- The authors declare that there is no potential conflict of interest in the study, 
      or in the authorship and publication of this article.
EDAT- 2022/10/28 06:00
MHDA- 2022/10/29 06:00
PMCR- 2022/10/17
CRDT- 2022/10/27 01:38
PHST- 2022/08/08 00:00 [received]
PHST- 2022/09/17 00:00 [revised]
PHST- 2022/10/12 00:00 [accepted]
PHST- 2022/10/27 01:38 [entrez]
PHST- 2022/10/28 06:00 [pubmed]
PHST- 2022/10/29 06:00 [medline]
PHST- 2022/10/17 00:00 [pmc-release]
AID - medicina58101473 [pii]
AID - medicina-58-01473 [pii]
AID - 10.3390/medicina58101473 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2022 Oct 17;58(10):1473. doi: 10.3390/medicina58101473.